Cotinine is an Unreliable Biomarker for Systemic Exposure in Spit Tobacco Users Jon O. Ebbert, MD, MSc Lowell C. Dale, MD Liza Nirelli Darrell Schroeder,

Slides:



Advertisements
Similar presentations
NC STEP/Mission Hospitals School Cessation and Treatment Guide.
Advertisements

In the name of GOD Decreasing smoking behavior and risk through CYP2A6 inhibition Shadi Sarahroodi (Pharm.D) Ahvaz Jondishapour University of medical.
ABCs of Behavioral Support Jonathan Foulds PhD. Penn State – College of Medicine
Treatment of Tobacco Dependence in 2012 J. Taylor Hays, MD Professor of Medicine Associate Director Nicotine Dependence Center Mayo Clinic Rochester, MN.
© 2003 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH. ALL RIGHTS RESERVED Smokeless (Spit) Tobacco Use: Comprehensive Treatment Model Lowell C. Dale,
Bitter Taste Phenotype & Oral NRT Adherence Karen Ahijevych, PhD, RN, FAAN Professor and Associate Dean for Academic Affairs.
Translational Research in Tobacco Dependence Treatment Caryn Lerman, Ph.D. Deputy Director Abramson Cancer Center University of Pennsylvania.
Depression and smoking: Treatments Lirio S. Covey, Ph.D. Columbia University New York State Psychiatric Institute New York, NY, U.S.A.
Treating Nicotine Dependence in Patients with Addictive Disorders Eric Heiligenstein, M.D. Director of Psychiatry University Health Services University.
Does Improvement in Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) Mediate an Effect of Long- Acting OROS-Methylphenidate on Cigarette Smoking?
Causal Inference and Alternative Explanations S.A. Murphy Univ. of Michigan May, 2004.
1 Treatment of Spit Tobacco Use Lowell C. Dale, MD Jon O. Ebbert, MD, MSc Assistant Professors of Medicine, Mayo Medical School Community Internal Medicine.
Does Web-Based ACT Help Smokers with Depressive Symptoms to Quit? Helen A. Jones University of Washington Fred Hutchinson Cancer Research Center, Seattle.
Treating Tobacco Dependence in Patients with Other Addictions Richard D. Hurt, M.D. Professor of Medicine, Mayo Clinic College of Medicine Director, Nicotine.
Communication Interactive Health Communication and Work Site Health Promotion Robin G. Molella, MD, Candace K. Kolars, PhD, MPH, Neil R. Sullivan, MPH,
TREVOR VAN MIERLO, BA(HONS), MSCCH (C) PETER SELBY, MBBS, CCFP, MCSC, ASAM, MRO Web Assisted Tobacco Interventions in 2009: A Review of the Current Research.
Using 5 A’s and Incentives to Promote Prenatal Smoking Cessation PI: Rebecca J. Donatelle, PhD, CHES PC: Deanne Hudson, RN, MPH, CHES Co-PI: Edward Lichtenstein,
ALCOHOL USE REDUCTION IN THE COURSE OF SMOKING CESSATION TREATMENT: A REVIEW Robert F. Leeman Stephanie S. O’Malley Yale University School of Medicine.
Neurobiology of Tobacco Dependence and Current Best Treatments
Demonstration of a Process- Outcome Link for Smoking Cessation Melissa M. Farmer, PhD 1,2 Elizabeth M. Yano, PhD 1,2 Brian S. Mittman, PhD 1,2 Scott E.
Nicotine Dependence Laurie Zawertailo, PhD Adjunct Research Scientist Clinical Neuroscience, CAMH.
Can undergoing an internet based ACT intervention change the impact of predictors thought to lead to Substance Use? Leonidou. G., Savvides. S., N. & Karekla.
1 Hans J Roethig, Philip Morris USA, LSRO Presentation, 11, 6, 03; for discussion only Clinical Exposure Evaluation Hans J. Roethig, MD, PhD, FCP, FFPM.
Clinical Pharmacokinetics. Clinical Pharmacodynamics. Drugs’ Interaction. Adverse Effects of Drugs.
Effect of Depression on Smoking Cessation Outcomes Sonne SC 1, Nunes EV 2, Jiang H 2, Gan W 2, Tyson C 1, Reid MS 3 1 Medical University of South Carolina,
Theoretical Error Rates of Qualitative UDS Tests for Stimulants Neal Oden, PhD, Paul VanVeldhuisen, PhD, NIDA Data and Statistics Center 2, The EMMES Corporation.
CCTN September 6 th, Recent Scientific Publications from the Clinical Trials Network David Liu, M.D. (CTN-0029) Harold Perl, Ph.D. (CTN-0015) Paul.
GENES and TOBACCO USE. CAN GENES PREDICT WHO WILL… develop heart disease? develop lung cancer? become a smoker? be able to quit?
OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: Racial/ethnic differences Lirio S. Covey, 1 Mei-Chen Hu,
Maternal Smoking and Infant Birth Weight Lucinda England, MD, MSPH National Institute of Child Health and Human Development (NICHD)
A Placebo-Controlled Trial of Selegiline Hydrochloride for Smoking Cessation Tony P. George, M.D., Jennifer Vessicchio, M.S.W., Angelo Termine, B.S., Peter.
Emerging Evidence for the Role of Polymorphic Drug Metabolizing Enzymes in Smoking Behavior and Treatment Caryn Lerman & Rachel Tyndale University of Pennsylvania.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
1 Impact of Depression History on Tobacco Withdrawal and Relapse Among Female Smokers David W. Wetter, Ph.D. Department of Behavioral Science Funded by.
Addressing Nicotine Dependence in Drug Treatment Kimber Paschall Richter, PhD, MPH Robert M. McCool, MS University of Kansas School of Medicine, Kansas.
Pharmaceutics I صيدلانيات 1 Unit 2 Route of Drug Administration
DiFranza et al Unger et al Zoe, Jesse, Matt, Syrah.
What the National Institute on Drug Abuse’s Clinical Trials Network Can Do for You? Major Findings from Medication Trials and Implications for Community-Based.
Foundation Knowledge and Skills
Varenicline: A Tale of Three Molecules Douglas E. Jorenby, Ph.D. Associate Professor of Medicine Univ. of WI School of Medicine and Public Health The Center.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Introduction Conclusions Liver transplant recipients with impaired renal function or a low dose-adjusted tacrolimus concentration suggesting a high CYP3A4.
Lab 16. tobacco Nicotine Nicotine is the active ingredient in tobacco. Although this drug is not currently used therapeutically(except in smoking.
NICOTINE PHARMACOLOGY and PRINCIPLES of ADDICTION
Involving Patients with Low Risk Chest Pain in Discharge Decisions: A Multicenter Trial Erik P. Hess MD MSc.
1 Tobacco Cessation A Brief Intervention Makes a Difference! October 2007 MaryAnne Waters Tobacco Reduction Coordinator - Interior Health Authority.
1 Effects on smoking cessation of a national strategy to maximise NRT usage: the UK experience Robert West University College London WCTOH July 2006 Washington.
Self-titration by experienced e- cigarette users: Blood nicotine delivery and subjective effects Lynne Dawkins (LSBU), Catherine Kimber (UEL), Mira Doig.
Utilization of a Telephone Quitline by Smokeless Tobacco Users Lowell C. Dale, MD Associate Professor of Medicine College of Medicine, Mayo Clinic Medical.
Effects of smoking on MAN
6 myths and facts about tobacco use disorder in people with mental health and substance use disorders Associate Professor.
Sharon S. Allen, MD, PhD, Tracy Bade, MPH, Bruce A. Center, PhD,
Volume 387, Issue 10037, Pages (June 2016)
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Smoking Cessation: Different Modalities and LDL Level Change with Quitting Sadia Anees Ali, MD Cook County-Loyola-Provident Family Medicine Residency.
Use of biomarkers in smoking cessation trials
Get smoker to their baseline for their behavioral health condition and initiating abstinence from substances. Then assess whether, in the past year, was.
ABCs of Behavioral Support
Wenjun Zhong, PhD, Hilal Maradit-Kremers, MD, MSc, Jennifer L. St
Smoking Behaviour Phenotypes and Measurement Precision
EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.
이 장 우.
Treating Tobacco Dependence in Light of the 2008 US Department of Health and Human Services Clinical Practice Guideline  J. Taylor Hays, MD, Jon O. Ebbert,
Microbial contribution to drug metabolism.
Counseling Patients on the Use of Electronic Cigarettes
Overview of Substance Use Outcomes in Other SUD trials
Matthew T. Sutherland, Elliot A. Stein  Trends in Molecular Medicine 
Thomas P. Moyer, PhD, Dennis J. O'Kane, PhD, Linnea M
Margaret B. Nolan, MD, David O. Warner, MD  Mayo Clinic Proceedings 
Plasma cotinine concentration over the weeks of the study during progressive reduction of the nicotine content of cigarettes (weeks 1–6) and after returning.
Presentation transcript:

Cotinine is an Unreliable Biomarker for Systemic Exposure in Spit Tobacco Users Jon O. Ebbert, MD, MSc Lowell C. Dale, MD Liza Nirelli Darrell Schroeder, MS Thomas Moyer, PhD Richard D. Hurt, MD Mayo Clinic Rochester, MN Jon O. Ebbert, MD, MSc Lowell C. Dale, MD Liza Nirelli Darrell Schroeder, MS Thomas Moyer, PhD Richard D. Hurt, MD Mayo Clinic Rochester, MN

Ebbert et al. Addictive Behaviors, in press Background Spit tobacco (ST) users absorb nicotine both through the buccal mucosa and the gastrointestinal tract Spit tobacco (ST) users absorb nicotine both through the buccal mucosa and the gastrointestinal tract (Benowitz, 1989) Swallowed nicotine is known to enter the portal circulation through the small intestine and undergo first-pass metabolism by the liver Swallowed nicotine is known to enter the portal circulation through the small intestine and undergo first-pass metabolism by the liver Spit tobacco (ST) users absorb nicotine both through the buccal mucosa and the gastrointestinal tract Spit tobacco (ST) users absorb nicotine both through the buccal mucosa and the gastrointestinal tract (Benowitz, 1989) Swallowed nicotine is known to enter the portal circulation through the small intestine and undergo first-pass metabolism by the liver Swallowed nicotine is known to enter the portal circulation through the small intestine and undergo first-pass metabolism by the liver

Ebbert et al. Addictive Behaviors, in press Background Nicotine entering the liver through the portal circulation is converted to cotinine and other metabolites before reaching the systemic circulation Cotinine is pharmacologically inactive Contributes to the higher serum cotinine concentrations observed in ST users compared with cigarette smokers (Benowitz, 1989) Nicotine entering the liver through the portal circulation is converted to cotinine and other metabolites before reaching the systemic circulation Cotinine is pharmacologically inactive Contributes to the higher serum cotinine concentrations observed in ST users compared with cigarette smokers (Benowitz, 1989)

Ebbert et al. Addictive Behaviors, in press Hypothesis Cotinine may be an inaccurate measure of systemic nicotine exposure in ST users if cotinine positively correlates with the amount of tobacco juice that is swallowed.

Ebbert et al. Addictive Behaviors, in press Methods Used data obtained from 68 daily ST users enrolled in a randomized, controlled clinical trial of bupropion for ST users (Dale, 2002) Correlated baseline serum nicotine and cotinine concentrations with clinical measures of ST dependence Items from the modified FTQ for ST users (Boyle, 1995) Used data obtained from 68 daily ST users enrolled in a randomized, controlled clinical trial of bupropion for ST users (Dale, 2002) Correlated baseline serum nicotine and cotinine concentrations with clinical measures of ST dependence Items from the modified FTQ for ST users (Boyle, 1995)

Ebbert et al. Addictive Behaviors, in press Spit Tobacco & Bupropion: Pilot Study

Ebbert et al. Addictive Behaviors, in press Table 2. Association of Tobacco Usage Variables with Serum Nicotine and Cotinine

Ebbert et al. Addictive Behaviors, in press

Conclusions Nicotine may more accurately reflect systemic exposure to nicotine than cotinine in ST users

Ebbert et al. Addictive Behaviors, in press Clinical Implications Nicotine may be preferred when accurate measures of systemic exposure to nicotine are needed Tailoring nicotine patch dose Nicotine may be preferred when using biomarkers to predict: Withdrawal Abstinence outcomes Nicotine may be preferred when accurate measures of systemic exposure to nicotine are needed Tailoring nicotine patch dose Nicotine may be preferred when using biomarkers to predict: Withdrawal Abstinence outcomes

Ebbert et al. Addictive Behaviors, in press Clinical Implications Nicotine may be preferred when developing clinical scales for nicotine dependence in ST users